KR910005883A - 조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물 - Google Patents

조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물 Download PDF

Info

Publication number
KR910005883A
KR910005883A KR1019900015031A KR900015031A KR910005883A KR 910005883 A KR910005883 A KR 910005883A KR 1019900015031 A KR1019900015031 A KR 1019900015031A KR 900015031 A KR900015031 A KR 900015031A KR 910005883 A KR910005883 A KR 910005883A
Authority
KR
South Korea
Prior art keywords
acid
salt
composition according
thrombolytic composition
thrombolytic
Prior art date
Application number
KR1019900015031A
Other languages
English (en)
Other versions
KR930008908B1 (ko
Inventor
유끼오 시마자끼
미유끼 가와시마
마사히꼬 이시바시
료 다나까
기요시 사까이
히사히로 이시와리
Original Assignee
원본미기재
미쯔이도오아쓰 가가꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 미쯔이도오아쓰 가가꾸 가부시끼가이샤 filed Critical 원본미기재
Publication of KR910005883A publication Critical patent/KR910005883A/ko
Application granted granted Critical
Publication of KR930008908B1 publication Critical patent/KR930008908B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈정용해 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (17)

  1. 조직형 플라스미노겐 활성화제 또는 그의 유도체, 음이온성 중합체 또는 그의 염 및 아민 화합물 또는 그의 염을 함유하는 혈전용해 조성물.
  2. 조직형 플라스미노겐 활성화제 또는 그의 유도체, 음이온성 중합체 또는 그의 염, 아민 화합물 및 산 또는 그의 염을 함유하는 혈전용해 조성물.
  3. 제1항에 있어서, 음이온성 중합체가 염이고 아민 화합물이 염인 혈전용해 조성물.
  4. 제2항에 있어서, 음이온성 중합체가 염인 혈전용해 조성물.
  5. 제1항 또는 2항에 있어서, 음이온성 중합체 또는 그의 염이 조직형 플라스미노겐 활성화제 또는 그의 유도체 1mg당 20㎍이상의 농도로 존재하는 혈전용해 조성물.
  6. 제1항 또는 2항에 있어서, 아민 화합물 또는 그의 염이 조직형 플라스미노겐 활성화제 또는 그의 유도체 1mg당 20마이크로몰~10 밀리몰의 농도로 존재하는 혈전용해 조성물.
  7. 제2항에 있어서, 산 또는 그의 염이 조직형 플라스미노겐 활성화제 또는 그의 유도체 1mg당 20 마이크로몰~10밀리몰의 농도로 존재하는 혈전용해 조성물.
  8. 제1항 또는 2항에 있어서, 음이온성 중합체의 음이온 잔기가 카르복실, 카르복시메틸, 황산기 또는 인산기로 이루어진 군에서 선택된 일종 이상의 것인 혈전용해 조성물.
  9. 제1항 또는 2항에 있어서, 아민 화합물 또는 그의 염이 모노에탄올아민, 디에탄올아민, 트리메탄올아민, 폴리에틸렌이민, 아르기닌, 리신, 히스리딘 및 그의 염으로 이루어진 군에서 선택된 일종 이상의 것인 혈전용해 조성물.
  10. 제2항에 있어서, 산 또는 그의 염이 옥살산, 염산, 황산, 인산, 피로인산, 시트르산, 타르타르산, 말산, 말레산, 글루쿠폰산, 글루타르산, 락트산, 아디프산, 아스코르브산 및 그의 염으로 이루어진 군에서 선택된 일종 이상의 것인 혈전용해 조성물.
  11. 제1항 내지 4항중 어느 한 항에 있어서, 혈전용해 조성물이 수용액인 혈전용해 조성물.
  12. 제1항 내지 4항중 어느 한 항에 있어서, 혈전용해 조성물이 동결전조제제인 혈전용해 조성물.
  13. 제11항에 있어서, 수용액중 조직형 플라스미노겐 활성화제의 농도가 0.001~10mg/㎖인 혈전용해 조성물.
  14. 제13항에 있어서, 수용액의 PH가 5~9인 혈전용해 조성물.
  15. 제12항에 있어서, 동결건조 제제중 조직형 플라스미노겐 활성화제의 양이 0.1~10중량%인 혈전용해 조성물.
  16. 제11항 또는 12항에 기재된 혈전용해 조성물을 생리식염수에 용해시킨 주사용 수액.
  17. 제11항 또는 12항에 기재된 혈전용해 조성물을 5% 글루코오스 용액 및 주사용 증류수에 용해시킨 주사용 수액.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900015031A 1989-09-21 1990-09-21 조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물 KR930008908B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP243310/89 1989-09-21
JP24331089 1989-09-21
JP1-243310 1989-09-21

Publications (2)

Publication Number Publication Date
KR910005883A true KR910005883A (ko) 1991-04-27
KR930008908B1 KR930008908B1 (ko) 1993-09-17

Family

ID=17101932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900015031A KR930008908B1 (ko) 1989-09-21 1990-09-21 조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물

Country Status (15)

Country Link
US (1) US6051223A (ko)
EP (1) EP0419252B1 (ko)
JP (1) JP2520975B2 (ko)
KR (1) KR930008908B1 (ko)
CN (1) CN1041799C (ko)
AT (1) ATE86867T1 (ko)
BR (1) BR9004692A (ko)
CA (1) CA2025317C (ko)
DE (1) DE69001110T2 (ko)
DK (1) DK0419252T3 (ko)
ES (1) ES2054263T3 (ko)
FI (1) FI104953B (ko)
GR (1) GR3007396T3 (ko)
NO (1) NO904119L (ko)
NZ (1) NZ235298A (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
US5272076A (en) * 1991-06-13 1993-12-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
US6527979B2 (en) * 1999-08-27 2003-03-04 Corazon Technologies, Inc. Catheter systems and methods for their use in the treatment of calcified vascular occlusions
ES2728241T3 (es) * 2006-03-27 2019-10-23 Tms Co Ltd Proceso para la producción de compuestos de triprenilfenol
US9168233B2 (en) * 2012-06-11 2015-10-27 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
CN103191054B (zh) * 2013-04-19 2015-05-27 范克 一种肝素钠封管注射液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) * 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
JPS52145591A (en) * 1976-05-28 1977-12-03 Kanebo Ltd Stabilization of urokinase
JPS5467089A (en) * 1977-11-07 1979-05-30 Dainippon Pharmaceut Co Ltd Urokinase composition
JPS5568290A (en) * 1978-11-16 1980-05-22 Kanebo Ltd Stabilization of urokinase
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
JPS60158117A (ja) * 1984-01-30 1985-08-19 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
JPS60158116A (ja) * 1984-01-30 1985-08-19 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
JPS60184026A (ja) * 1984-03-01 1985-09-19 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助方法
JPS60181028A (ja) * 1984-02-29 1985-09-14 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助法
GR860624B (en) * 1985-03-06 1986-07-08 Survival Technology T-pa composition and method of getting into blood steam
DE3512910A1 (de) * 1985-04-11 1986-10-16 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung von plasminogenaktivatoren
DE3512909A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Verfahren zur bestimmung von plasminogenaktivatoren (pa)
DE3512908A1 (de) * 1985-04-11 1986-10-23 Behringwerke Ag, 3550 Marburg Gewebe-plasminogenaktivator (t-pa) enthaltendes mittel
CA1267602A (en) * 1985-09-10 1990-04-10 Fumio Kakimoto Composition containing tissue plasminogen activator
JPH0669960B2 (ja) * 1985-11-22 1994-09-07 エーザイ株式会社 水溶性を増加したｔＰＡ含有医薬組成物
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
JPH0678241B2 (ja) * 1986-04-02 1994-10-05 エーザイ株式会社 ｔＰＡ医薬組成物
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
JPH06226234A (ja) * 1993-02-01 1994-08-16 Shojiro Takeuchi 産業廃棄物の炭化処理方法
JPH06236332A (ja) * 1993-02-09 1994-08-23 Oki Electric Ind Co Ltd プログラムローディング装置
JPH06259221A (ja) * 1993-03-05 1994-09-16 Tokyo Electric Co Ltd 画面表示器を備えた情報処理装置
JPH06281326A (ja) * 1993-03-30 1994-10-07 Shibaura Eng Works Co Ltd 洗浄物の乾燥方法

Also Published As

Publication number Publication date
ES2054263T3 (es) 1994-08-01
BR9004692A (pt) 1991-09-10
CA2025317C (en) 1996-05-07
JP2520975B2 (ja) 1996-07-31
EP0419252A1 (en) 1991-03-27
ATE86867T1 (de) 1993-04-15
EP0419252B1 (en) 1993-03-17
AU6246790A (en) 1991-03-28
US6051223A (en) 2000-04-18
CN1041799C (zh) 1999-01-27
GR3007396T3 (ko) 1993-07-30
AU619697B2 (en) 1992-01-30
CN1050321A (zh) 1991-04-03
DK0419252T3 (da) 1993-04-19
NO904119D0 (no) 1990-09-20
NO904119L (no) 1991-03-22
DE69001110T2 (de) 1993-06-24
FI104953B (fi) 2000-05-15
NZ235298A (en) 1992-12-23
KR930008908B1 (ko) 1993-09-17
DE69001110D1 (de) 1993-04-22
JPH0418032A (ja) 1992-01-22
CA2025317A1 (en) 1991-03-22
FI904617A0 (fi) 1990-09-19

Similar Documents

Publication Publication Date Title
Manku et al. Indomethacin inhibits responses to all vasoconstrictors in the rat mesenteric vascular bed: restoration of responses by prostaglandin E2
Wojtczak et al. The inhibition of succinate dehydrogenase by oxaloacetate
KR850700216A (ko) 활성성분을 용해시키기 위한 방법 및 이로부터 얻어진 제약 조성물
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
EP1226829B1 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
KR890012634A (ko) 제약 조성물의 안정성을 개선시키는 방법
KR890000103A (ko) 조직 플라스미노겐 활성화제(t-PA) 활성을 갖는 단백질의 고농도 용액의 제조방법, t-PA 활성을 갖는 단백질을 함유하는 용액, 및 인체 및 수의약제에 있어서 용액의 용도
KR910005883A (ko) 조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물
KR910001068A (ko) 항생제
KR910000176A (ko) 맥관 형성 저해제
KR970706844A (ko) 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor)
JPS61143314A (ja) メラニン生成抑制用乳剤
DE69400190D1 (de) Verfahren zum herstellen von arzneizusammensetzungen, die vecuroniumbromid enthalten
JPS61143313A (ja) メラニン生成抑制用ロ−シヨン剤
KR880700805A (ko) 기능성 유기 염기를 주제로 하는 뇌질환 치료용 제약 조성물
Lowenthal et al. The Inhibition of Hyaluronidase by Sodium Salicylate and Its Possible Metabolites
Peters et al. The dissociating power of salts of fatty acids: Preliminary paper
Fabianek et al. Effects of ascorbic acids and flavonoids on permeability of dermal connective tissue in rats and guinea pigs
KR910000154A (ko) 안정화된 피록시캄 주사액조성물과 그 제조방법
Roschlau et al. Pharmacological modification of the vascular response to systemically administered thrombolytic enzymes (CA-7)
Kumar et al. Inactivation of chicken liver fatty acid synthetase by malonyl CoA
Forbes et al. Effect of certain hendecynoic acids and their ammonium salts on acid production in saliva containing glucose
Losowsky et al. Evidence for a new coagulation factor
MX9603766A (es) Metodos de administracion de benzamidas n-substituidas o fenotiazinas.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010912

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee